Updated Jul 16, 2026
Gline Matthew has filed 2 SEC Form 4 filings across 1 company in the last 90 days — active on both sides. Lifetime open-market purchases: $50K. Lifetime open-market sales: $46.17M.
Matthew Gline is the CEO of Roivant Sciences Ltd., a biopharmaceutical company focused on improving healthcare delivery. He has been involved in various roles within the company, contributing to its growth and the development of its drug candidates.
| Role | CEO, Director |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | ROIV | Roivant Sciences Ltd. | F — Tax withholding / forfeiture | 76.2K | $35.39 | $2.70M |
| 2026-04-20 | ROIV | Roivant Sciences Ltd. | S — Open-market sale | 289.8K | $29.16 | $8.45M |
| 2026-04-01 | ROIV | Roivant Sciences Ltd. | F — Tax withholding / forfeiture | 304.7K | $27.70 | $8.44M |
| 2026-04-01 | ROIV | Roivant Sciences Ltd. | F — Tax withholding / forfeiture | 53.8K | $26.41 | $1.42M |
| 2026-04-01 | ROIV | Roivant Sciences Ltd. | M — Option exercise | 97.3K | — | |
| 2025-12-18 | ROIV | Roivant Sciences Ltd. | J — Other acquisition / disposition | 1.33M | $21.68 | $28.82M |
| 2025-12-18 | ROIV | Roivant Sciences Ltd. | S — Open-market sale | 943.5K | $21.68 | $20.46M |
| 2025-12-18 | ROIV | Roivant Sciences Ltd. | M — Option exercise | 2.27M | $12.68 | $28.82M |
| 2025-12-18 | ROIV | Roivant Sciences Ltd. | J — Other acquisition / disposition | 797.6K | $21.68 | $17.29M |
| 2025-12-18 | ROIV | Roivant Sciences Ltd. | S — Open-market sale | 566.1K | $21.68 | $12.27M |
| 2025-12-18 | ROIV | Roivant Sciences Ltd. | M — Option exercise | 1.36M | $12.68 | $17.29M |
| 2025-12-18 | ROIV | Roivant Sciences Ltd. | J — Other acquisition / disposition | 3.7K | $21.68 | $81K |
| 2025-12-18 | ROIV | Roivant Sciences Ltd. | S — Open-market sale | 230.4K | $21.68 | $4.99M |
| 2025-12-18 | ROIV | Roivant Sciences Ltd. | M — Option exercise | 234.1K | $4.06 | $950K |
| 2025-09-18 | ROIV | Roivant Sciences Ltd. | P — Open-market purchase | 3.3K | $15.07 | $50K |
| 2024-12-26 | ROIV | Roivant Sciences Ltd. | F — Tax withholding / forfeiture | 10.9K | $11.57 | $127K |
| 2024-11-22 | ROIV | Roivant Sciences Ltd. | F — Tax withholding / forfeiture | 10.9K | $11.49 | $126K |
| 2024-10-22 | ROIV | Roivant Sciences Ltd. | F — Tax withholding / forfeiture | 10.9K | $11.92 | $130K |
Matthew Gline is the CEO of Roivant Sciences Ltd., a biopharmaceutical company focused on improving healthcare delivery. He has been involved in various roles within the company, contributing to its growth and the development of its drug candidates.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($50K) and 4 open-market sales ($46.17M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Gline Matthew profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.